# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k072078   
B. Purpose for Submission: Addition of the urine matrix to the assay procedure   
C. Measurand: Beta-2-microglobulin   
D. Type of Test: Latex particle enhanced immunoturbidimetric assay   
E. Applicant: Biokit S.A.   
F. Proprietary and Established Names: Quantia Beta-2 Microglobulin   
G. Regulatory Information:

<table><tr><td>Product Code</td><td>Classification</td><td>Regulation Section</td><td>Panel</td></tr><tr><td>System, Test, Beta- 2-Microglobulin Immunological (JZG)</td><td>Class II</td><td>21 CFR 866.5630, Beta-2- microglobulin immunological test system.</td><td>82 IMMUNOLOGY (IM)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

The Quantia Beta-2 Microglobulin is intended as a latex particle enhanced immunoturbidimetric assay for the in vitro quantitative determination of beta-2- microglobulin concentration in human serum, plasma (EDTA) or urine on the AEROSET $^ \mathrm { \textregistered }$ Instrument as an aid in the diagnosis of active rheumatoid arthritis and kidney disease.

The Quantia Beta-2 Microglobulin is intended to be used with the already cleared Quantia PROTEINS Control (k050596) and the Beta-2 Microglobulin Standard (k050613).

2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: The reagents are for use on the Abbott AEROSET $^ \mathrm { \textregistered }$ instrument

# I. Device Description:

The Quantia Beta-2 Microglobulin kit contains 4 bottles of Reagent 1 (R1) (6 mL each) and 4 bottles of Reagent 2 (R2) ( $3 \mathrm { m L }$ each). R1 buffer is sodium dihydrogen phosphate dihydrate with polyethylene glycol and preservative (sodium azide). R2 is a suspension of polystyrene latex particles of uniform size coated with the IgG fraction of rabbit anti-human Beta-2-microglobulin specific serum with preservative (sodium azide).

# J. Substantial Equivalence Information:

<table><tr><td>Predicate: IL Test Beta-2-Microglobulin</td><td>K943686</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Similarities:</td></tr><tr><td colspan="2">The Quantia Beta-2 Microglobulin and the IL Test Beta-2-Microglobulin are both manufactured by Biokit and are both intended for the quantitative in vitro diagnostic determination of beta-2-microglubulin. They also use the same methodology: Particle Enhanced Immunoturbidimetry. The Quantia Beta-2 Microglobulin and the IL Test Beta-2- Microglobulin, have the same composition: Latex Reagent Suspension of polystyrene latex particles coated with rabbit IgG anti-human Beta-2 Microglobulin in a buffer containing bovine serum albumin and &lt;</td></tr><tr><td colspan="2">0.1 % w/w sodium azide; and Reaction Buffer Phosphate buffer 40mM containing bovine serum albumin and sodium azide &lt; 0.1 % w/w.</td></tr><tr><td colspan="2">Differences: Specimen type: both assays can use serum and urine as samples. They differ in the plasma types. The device can use EDTA and the predicate can use EDTA and sodium</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>CLSI Interference Testing in Clinical Chemistry; Approved Guideline (EP 7-A) CLSI Method Comparison and Bias Estimation Using Patient Samples; Approved</td></tr><tr><td>Guideline (EP09-A2)</td></tr><tr><td>CLSI Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline (EP5-A)</td></tr></table>

# L. Test Principle:

When a sample containing Beta-2 Microglobulin is mixed with the reagent, a clear agglutination occurs which can be measured by turbidimetry. Results are expressed in $\mathrm { m g / L }$ of Beta-2-microglobulin based on the $1 ^ { \mathrm { s t } }$ WHO International Standard (B2M) established in 1985.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: CLSI EP5-A was followed.

<table><tr><td rowspan=1 colspan=1>Samples/Runs</td><td rowspan=1 colspan=1>Mean (mg/L)</td><td rowspan=1 colspan=1>CV (%) Within Run</td><td rowspan=1 colspan=1>CV (%) Total</td></tr><tr><td rowspan=1 colspan=1>2/40</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>2/40</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>2/40</td><td rowspan=1 colspan=1>0.204</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>2/40</td><td rowspan=1 colspan=1>0.302</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.3</td></tr></table>

# $b$ . Linearity/assay reportable range:

Linearity was assessed according to CLSI EP6-A. The overall reportable range for serum, plasma and urine is 0.025 to $9 6 ~ \mathrm { { m g / L } }$ . The assay was linear from 0.025 to $1 . 6 \mathrm { m g / L }$ (the reportable range for urine samples) with the automatic rerun capability (Dilution Protocol 2); from 0.25 to $1 6 \mathrm { m g / L }$ without the automatic rerun capability; and from16 to $9 6 ~ \mathrm { { m g / L } }$ with the automatic rerun capability (Dilution Protocol 1).

# Prozone

The manufacturer was asked to run a sample higher than $1 1 4 \mathrm { m g / L }$ to demonstrate the instrument give a result of ${ \bf \dot { \tau } } > 1 6 \mathrm { m g / L }$ . They tested samples from 80.4 to $2 0 0 . 9 \mathrm { m g / L }$ . In all cases the instrument gave a result of $> 9 6$ (serum linearity upper limit) and triggered the Dilution Protocol 1. The assay did not demonstrate prozone effect with specimens up to $2 0 0 \mathrm { m g / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The assay calibrators are standardized against WHO reference material B2M. Stability of the reagents was established at 19 months by testing 4 different lots. Reagents should be stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

d. Detection limit:

The limit of quantitation (LOQ) was defined as the minimum quantity of analyte that can be measured with a within-run CV below $20 \%$ and an error below $20 \%$ . The LOQ for the assay was determined to be $0 . 2 5 ~ \mathrm { m g / L }$ without the automatic rerun capability and $0 . 0 2 5 \mathrm { m g / L }$ with the automatic rerun capability for serum, plasma and urine. This was established by running serial dilutions of the $4 \mathrm { m g / L }$ calibrator. Through $0 . 0 2 5 \mathrm { m g / L }$ the $\% \mathrm { C V }$ ranged from 1.0 to $5 . 5 \%$ and error ranged from 3.8 to $9 . 3 \%$ .

The limit of detection (LOD) was defined as the mean reported value $+ 2 \mathrm { S D }$ for a sample free of analyte. The LOD was determined to be $0 . 0 4 6 \mathrm { { m g / L } }$ without the rerun capability and $0 . 0 2 5 \mathrm { m g / L }$ (LOQ) with the automatic rerun capability.

e. Analytical specificity:

CLSI guideline EP7-A was followed.

<table><tr><td rowspan=1 colspan=1>Substance tested</td><td rowspan=1 colspan=1>Concentration (mg/dL)</td><td rowspan=1 colspan=1>Outcome</td></tr><tr><td rowspan=1 colspan=1>Conjugated bilirubin</td><td rowspan=1 colspan=1>20.9</td><td rowspan=1 colspan=1>No interference</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>Interference below 10%</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>Interference below 10%</td></tr><tr><td rowspan=1 colspan=1>Protein (IgG)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>No interference</td></tr></table>

Urine pH showed no significant positive or negative influence on the result.

f. Assay cut-off: See Expected values/Reference range

2. Comparison studies:

a. Method comparison with predicate device: The comparison studies were performed using 110 urine samples with values ranging from 0.01 to $1 8 . 8 5 \mathrm { m g / L }$ . The required specifications were: Slope 1.0 $\pm 0 . 2 0$ ; and correlation coefficient $\Gamma \geq 0 . 9 5 0$ . The following results were obtained:

AEROSET versus ILab 900   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Outcome</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.088 (95% CI: 1.061 to 1.127)</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.001 (95% CI: -0.003 to 0.002)</td></tr><tr><td rowspan=1 colspan=1>Range (mg/L)</td><td rowspan=1 colspan=1>0.01- 18.85</td></tr><tr><td rowspan=1 colspan=1>Mean x (mg/L)</td><td rowspan=1 colspan=1>2.47</td></tr><tr><td rowspan=1 colspan=1>Mean y (mg/L)</td><td rowspan=1 colspan=1>2.467</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.9894</td></tr></table>

b. Matrix comparison:

Urine was the only matrix compared.

3. Clinical studies:

a. Clinical Sensitivity: Not determined   
$b$ . Clinical specificity: Not determined   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not determined

5. Expected values/Reference range: Concentrations of Beta-2-microglobulin in urine from healthy subjects averaged $0 . 0 9 8 \mathrm { m g / L }$ with an upper normal limit of $0 . 3 2 \mathrm { m g / L }$ (literature).

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantially equivalent decision.